GALECTIN THERAPEUTICS INC (GALT)
2025-06-30 | ||||
|---|---|---|---|---|
| Preferred stock dividends | 63 | |||
| Research and development | 3,261 | |||
| General and administrative | 1,364 | |||
| Total operating expenses | 4,625 | |||
| Total operating loss | -4,625 | |||
| Interest income | 26 | |||
| Interest expense | 1,826 | |||
| Change in fair value of derivative | -1,096 | |||
| Total other income (expense) | -2,896 | |||
| Net loss | -7,521 | |||
| Net loss applicable to common stockholders | -7,584 | |||
| Net loss per common share basic (in dollars per share) | -0.12 | |||
| Net loss per common share diluted (in dollars per share) | -0.12 | |||
| Weighted average common shares outstanding basic (in shares) | 63,447,000 | |||
| Weighted average common shares outstanding diluted (in shares) | 63,447,000 | |||